Group 1 - The core point of the news is that Jiahe Meikang's stock price has dropped by 5.07%, currently trading at 23.05 yuan per share, with a total market capitalization of 3.171 billion yuan [1] - Jiahe Meikang (Beijing) Technology Co., Ltd. was established on March 3, 2006, and went public on December 14, 2021. The company specializes in the research and industrialization of medical information software [1] - The revenue composition of Jiahe Meikang includes: software development and technical services (42.39%), self-developed software sales (37.64%), purchased software and hardware sales (19.86%), and other service sales (0.11%) [1] Group 2 - From the perspective of fund holdings, one fund under Taixin Fund has Jiahe Meikang as a major holding. The Taixin Internet + Theme Mixed A Fund (001978) held 6,947 shares in the third quarter, accounting for 4.93% of the fund's net value, making it the largest holding [2] - The Taixin Internet + Theme Mixed A Fund (001978) was established on June 8, 2016, with a latest scale of 4.2898 million. It has experienced a loss of 6.04% this year, ranking 8,110 out of 8,159 in its category [2] - The fund manager of Taixin Internet + Theme Mixed A is Chen Ying, who has been in the position for 3 years and 348 days, with a total asset scale of 540 million yuan. The best fund return during the tenure is 15.67%, while the worst is -14.68% [3]

Group 1 - The core viewpoint of the news is that 嘉和美康 (Jiahe Meikang) experienced a decline in stock price and significant changes in financing and shareholder structure, indicating potential challenges in its financial performance and market position [1][2]. Group 2 - On December 24, 嘉和美康's stock fell by 2.41%, with a trading volume of 119 million yuan. The financing data showed a net financing outflow of 1.46 million yuan, with a total financing balance of 186 million yuan, accounting for 5.64% of the circulating market value [1]. - The company’s financing balance is above the 70th percentile of the past year, indicating a relatively high level of financing activity [1]. - 嘉和美康's short selling data on December 24 showed no shares were sold or repaid, with a short selling balance of 13,500 shares, which is above the 90th percentile of the past year [1]. - As of November 10, 嘉和美康 had 8,866 shareholders, an increase of 16.78%, while the average number of circulating shares per shareholder decreased by 14.37% [2]. - For the period from January to September 2025, 嘉和美康 reported a revenue of 330 million yuan, a year-on-year decrease of 30.67%, and a net profit attributable to shareholders of -174 million yuan, a significant decline of 320.68% [2]. - Among the top ten circulating shareholders, 长城消费增值混合A (Changcheng Consumption Value Mixed A) held 2.00 million shares, a decrease of 410,000 shares compared to the previous period [2].

Group 1 - The core viewpoint of the news is that 嘉和美康 experienced a significant decline in stock price and financial performance, indicating potential challenges for the company [1][2]. Group 2 - On December 23, 嘉和美康's stock price dropped by 5.15%, with a trading volume of 145 million yuan. The financing data showed a net financing outflow of 770,700 yuan for the day [1]. - As of December 23, 嘉和美康's total margin trading balance was 187 million yuan, accounting for 5.55% of its market capitalization, which is above the 80th percentile of the past year [1]. - The company had no short selling activity on December 23, with a short selling balance of 331,000 yuan, also above the 90th percentile of the past year [1]. - 嘉和美康's main business includes medical information software development and commercialization, with revenue composition being 42.39% from software development and technical services, 37.64% from self-developed software sales, and 19.86% from purchased software and hardware sales [1]. Group 3 - As of November 10, 嘉和美康 had 8,866 shareholders, an increase of 16.78%, while the average circulating shares per person decreased by 14.37% [2]. - For the period from January to September 2025, 嘉和美康 reported a revenue of 330 million yuan, a year-on-year decrease of 30.67%, and a net profit attributable to shareholders of -174 million yuan, a year-on-year decrease of 320.68% [2]. - Among the top ten circulating shareholders as of September 30, 2025, 长城消费增值混合A held 2.001 million shares, a decrease of 410,000 shares compared to the previous period [2].

Group 1 - The core point of the news is that Jiahe Meikang's stock price dropped by 5.03% to 24.52 yuan per share, with a trading volume of 1.23 billion yuan and a turnover rate of 3.56%, resulting in a total market capitalization of 3.374 billion yuan [1] - Jiahe Meikang (Beijing) Technology Co., Ltd. was established on March 3, 2006, and went public on December 14, 2021. The company specializes in the research and industrialization of medical information software [1] - The revenue composition of Jiahe Meikang includes software development and technical services at 42.39%, self-developed software sales at 37.64%, purchased software and hardware sales at 19.86%, and other service sales at 0.11% [1] Group 2 - From the perspective of major fund holdings, the Guoxin Guozheng Fund has one fund heavily invested in Jiahe Meikang. The Guoxin Guozheng Xinli A (001797) held 9,000 shares in the third quarter, unchanged from the previous period, accounting for 1.26% of the fund's net value, ranking as the eighth largest holding [2] - The Guoxin Guozheng Xinli A (001797) was established on September 2, 2015, with a latest scale of 20.6671 million. Year-to-date returns are 11.34%, ranking 5,539 out of 8,088 in its category; the one-year return is 9.78%, ranking 5,659 out of 8,057; and since inception, it has incurred a loss of 13.6% [2]

Group 1 - The core viewpoint of the news is that Jiahe Meikang has seen a stock price increase of 5.27%, reaching 24.15 yuan per share, with a total market capitalization of 3.323 billion yuan [1] - Jiahe Meikang specializes in the research and industrialization of medical information software, with its main business revenue composition being 42.39% from software development and technical services, 37.64% from self-developed software sales, 19.86% from purchased software and hardware sales, and 0.11% from other service sales [1] Group 2 - The fund "Guoxin Guozheng New Profit A" holds 9,000 shares of Jiahe Meikang, unchanged from the previous period, representing 1.26% of the fund's net value, making it the eighth largest holding [2] - The fund has a total scale of 20.6671 million yuan and has achieved a year-to-date return of 11.86%, ranking 4940 out of 8209 in its category [2] - The fund manager, Zhang Honglei, has been in position for 4 years and 80 days, with the best fund return during his tenure being 39.01% and the worst being -13.4% [3]

Group 1 - On September 25, Jiahe Meikang's stock rose by 3.20%, with a trading volume of 93.32 million yuan [1] - The financing buy-in amount for Jiahe Meikang on that day was 22.23 million yuan, while the financing repayment was 11.74 million yuan, resulting in a net financing buy-in of 10.50 million yuan [1] - As of September 25, the total balance of margin trading for Jiahe Meikang was 193 million yuan, accounting for 4.73% of its market capitalization [1] Group 2 - As of June 30, the number of shareholders for Jiahe Meikang was 6,655, an increase of 12.93% compared to the previous period [2] - For the first half of 2025, Jiahe Meikang reported operating revenue of 219 million yuan, a year-on-year decrease of 27.22% [2] - The net profit attributable to the parent company for the same period was -116 million yuan, representing a year-on-year decrease of 323.29% [2] Group 3 - The main business of Jiahe Meikang includes medical information software development and industrialization, with revenue composition as follows: software development and technical services 42.39%, self-developed software sales 37.64%, purchased software and hardware sales 19.86%, and other service sales 0.11% [1]